Chronic Diseases and Injuries in Canada
Volume 32, no. 1, December 2011
Self-Monitoring Blood Glucose Workshop I: promoting meaningful dialogue and action at the provincial level
M. J. Dunbar, MEdAuthor references: Diabetes Care Program of Nova Scotia, Halifax, Nova Scotia, Canada
Correspondence: Margaret (Peggy) J. Dunbar, Suite 548 Bethune Building, 1276 South Park Street, Halifax, NS B3H 2Y9; Tel.: (902) 473-3209; Fax: (902) 473-3911; Email: email@example.com
The Nova Scotia Department of Health and Wellness supports a number of provincial programs, including the Diabetes Care Program of Nova Scotia (DCPNS), that function in an advisory capacity to the health department. Committed to ongoing improvement of the health care system and to the promotion of uniform standards throughout the province, these programs bring together experts / working groups to advise the system, recommend service delivery models, establish and monitor approved standards, guide policy and facilitate knowledge transfer/translation and networking in support of best/promising practices. The aim is to improve care and outcomes at the local, district and provincial levels. The development of the DCPNS Self-Monitoring Blood Glucose (SMBG) Decision Tool and the SMBG Workshop and related follow-up work are a cogent example of how a provincial program can quickly mobilize a broad range of experts and front-line health care providers to address an important issue like SMBG.
“Should all people with diabetes mellitus self-monitor their blood glucose?” This question has received increasing attention in recent years as individuals and the health care system struggle with costs related to testing, the limited evidence in support of testing for some populations, and the realities of using test results for persons with diabetes and their health care providers. This topic is not new. The American and Canadian Diabetes Associations hosted debates on SMBG during their national conferences, in 2005 and 2006 respectively. In November 2006, Alberta’s Institute of Health Economics hosted the first Canadian Consensus Conference on Self-Monitoring in Diabetes. National and international speakers presented clinical evidence as well as economic, policy and consumer perspectives. An expert panel assimilated the information and formulated responses to predetermined questions into a consensus document intended for use by all sectors in decision-making around SMBG in Canada.CADTH);
In January 2010, the DCPNS invited a multidisciplinary group of diabetes health care professionals to discuss the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) recommendations regarding SMBG for non-insulin-treated type 2 diabetes, specifically its use, frequency and application in Nova Scotia. Numerous local and national observers also attended the workshop to gain insight from the discussions (see Table 1).
Table 1. Invited participants and observers at the Diabetes Care Program of Nova Scotia (DCPNS) Self-Monitoring Blood Glucose (SMBG) Workshop
- Diabetes Centre educators from each of Nova Scotia’s nine district health authorities
- Registered nurses
- Professional dietitians
- Family physicians
- Specialist physicians
- Nurse practitioners
- Canadian Agency for Drugs and Technologies in Health (CADTH)
- Nova Scotia division of Canadian Diabetes Association (CDA)
- Pharmaceutical Services, Nova Scotia Department of Health and Wellness
- Drug Evaluation Unit, Capital District Health Authority (CDHA)
- Behaviour Change Institute, CDHA
- College of Pharmacy, Dalhousie University
- Academic Detailing, Dalhousie University
- Pharmacist, First Nations and Inuit Health, Atlantic Region, Health Canada
Participants were tested with the following:
- helping to formulate preliminary consensus recommendations, with the help of case-based discussions, on diagnostic strip usage for non-insulin-treated type 2 diabetes mellitus;
- identifying potential criteria for “exception status” in SMBG strip requirements for non-insulin-treated type 2 diabetes; and
- recommending next steps regarding patient and provider tools, supports and communications.
Four plenary sessions, focusing on the Nova Scotian context, contributed to understanding the evidence underlying the following COMPUS recommendation: “For most adults with type 2 diabetes using oral antidiabetes drugs (without insulin) or no antidiabetes drugs, the routine use of blood glucose test strips for SMBG is not recommended.”Table 2. Plenary sessions at the Diabetes Care Program of Nova Scotia (DCPNS) Self-Monitoring Blood Glucose (SMBG) Workshop Title Presenter Content Abbreviations: CADTH, Canadian Agency for Drugs and Technologies in Health; COMPUS, Canadian Optimal Medication Prescribing and Utilization Service; NS, Nova Scotia; SMBG, self-monitoring blood glucose. Self-Monitoring of Blood Glucose (SMBG): Highlights from CADTH’s Recommendations Denis Bélanger, BSc(Pharm), ACPR, Acting Senior Director, CADTH The first session provided insights into the COMPUS recommendation and the approach used to adopt optimal practice of SMBG. The presentation included an overview of available evidence about the clinical effectiveness and cost effectiveness of SMBG, potential opportunity costs and the key issues that were addressed in the recommendation deliberations. Self-Monitoring of Blood Glucose: The Health Care Professional Perspective Wayne Putnam, MD, Associate Professor, Department of Family Medicine, Dalhousie University This session provided preliminary findings from a qualitative study
The second half of the workshop focused on case-based discussions and small group work facilitated by clinical experts, Drs. Lynne Harrigan (Internist) and Dale Clayton (Endocrinologist). Cases moved from simple to complex and explored SMBG considerations related to diagnosis, degree of hyperglycemia, type of diabetes treatment, risk of hypoglycemia, and the influences of age, occupation, interest, cognition and motivation.
Participants were introduced to a draft SMBG Decision Tool developed by the DCPNS. The draft tool had three focal areas:
- instructions for how to use and interpret the tool;
- indications and considerations for SMBG (e.g. safety, planned use of the results by the individual and his/her health care team, and self-management education); and
- SMBG recommendations (e.g. specific examples of low and high intensity testing with a focus on “time-limited” testing).
Participants used the tool as they worked through seven cases studies, as they would be expected to do in practice. According to the participants, “the tool allowed for a more objective look at each individual case and removed emotion and subjectivity from the equation.” It allowed for a focus on patient safety, available evidence, an individual’s interest and capability, and the health care provider’s use of results. In cases for which testing is recommended, the tool also helped participants to determine the intensity of testing required (e.g. low-intensity versus time-limited, high intensity).
Following the case studies, participants committed to continuing the dialogue and refining the SMBG Decision Tool by responding to consensus questions and a “Needs and Wants” exercise via email. This feedback will help guide DCPNS and other partners in the development and delivery of resources and programs to move forward a more standardized approach to SMBG in Nova Scotia.
Through leadership and partnership, the DCPNS demonstrated the value of addressing the SMBG issue through local dialogue, decision, and provider and patient supports as well as planned, thoughtful dissemination strategies to increase reach into a variety of provider groups.
The DCPNS refined the SMBG Decision Tool and worked with its partners and other stakeholders to reach across provider groups to attain consistency in approach and messaging for SMBG in the non-insulin-treated type 2 diabetes population. The results of this continued work are reported in Part II of this article.11
The Diabetes Care Program of Nova Scotia would like to thank all the participants of the Self-Monitoring Blood Glucose Workshop for helping to guide this important work and the observers for their encouragement and support. In particular, we would like to acknowledge Bev Harpell, Brenda Cooke, and Dr. Lynne Harrigan for helping to shape the draft SMBG Decision Tool and the agenda for the SMBG Workshop. Last, but not least, we would like to thank Pam Talbot for her contributions toward the preparation of this manuscript.
- Institute of Health Economics. Consensus statement on self-monitoring in diabetes [Internet]. Edmonton (AB): Institute of Health Economics; 2006 Nov 14-16 [cited 2010 Aug 24]. Available from: http://www.ihe.ca/documents/consensus_statement_complete_nov17_0.pdf
- Latter C, McLean-Veysey P, Dunbar P, Frail D, Sketris I, Putnam W. Self-monitoring of blood glucose: what are health care professionals recommending? Can J Diabetes. 2011;35(1):31-9.
- Canadian Agency for Drugs and Technologies in Health. Optimal therapy recommendations for the prescribing and use of blood glucose test strips. Optimal Therapy Report – COMPUS [Internet]. Ottawa (ON): CADTH; 2009 Jul [cited 2010 Aug 24]. Available from: http://www.cadth.ca/media/pdf/compus_BGTS_OT_Rec_e.pdf
- Canadian Agency for Drugs and Technologies in Health. Current practice analysis of health care providers and patients on self-monitoring of blood glucose. Optimal Therapy Report – COMPUS [Internet]. Ottawa (ON): CADTH; 2009 Mar [cited 2010 Aug 24]. Available from:http://www.cadth.ca/media/pdf/compus_Current_Practice_Report_Vol-3-Issue-5.pdf
- Gomes T, Juurlink DN, Shah BR, Paterson JM, Mamdani MM. Blood glucose test strip use: patterns, costs and potential cost reduction associated with reduced testing. Toronto (ON): Institute for Clinical Evaluative Sciences; 2009 Dec [cited 2010 Aug 24]. 21 p. Available from: http://www.ices.on.ca/file/Blood%20Glucose%20Test%20Strip_Dec2009.pdf
- Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ [Internet]. 2007 Jul 21 [cited 2010 Aug 24];335(7611):132. Available from: http://www.bmj.com/cgi/reprint/335/7611/132 doi:10.1136/bmj.39247.447431.BE.
- Boutati EI, Raptis SA. Self-monitoring of blood glucose as part of the integral care of type 2 diabetes. Diabetes Care. 2009;32(Suppl2):S205-10.
- Cameron C, Coyle D, Ur E, Klarenbach S. Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. CMAJ [Internet]. 2010 Jan 12;182(1):28-34. Epub 2009 Dec 21 [cited 2010 Aug 24]. Available from: http://www.cmaj.ca/cgi/rapidpdf/cmaj.090765v1 doi:10.1503/cmaj.090765.
- Self Monitoring of Blood Glucose: An Essential Component of Diabetes Management? Preconference panel presentation at the International Diabetes Federation’s 20th World Diabetes Congress; 2009 Oct 18-22; Palais des Congrès de Montréal, Montréal (QC).
- International Diabetes Federation. Self-monitoring of blood glucose in non-insulin treated type 2 diabetes. Brussels (BE): International Diabetes Federation; 2009. 44 p. Available from: http://www.idf.org/webdata/docs/SMBG_EN2.pdf
- Dunbar MJ. Self-Monitoring Blood Glucose Workshop II: development and dissemination of the DCPNS decision tool for self-monitoring blood glucose in non-insulin-using type 2 diabetes. Chronic Dis Inj Can. 2011;32(1):59-61.
- Blood glucose self-monitoring: benefit is not proven for non-insulin-dependent patients with type 2 diabetes [press release on Internet]. Cologne (DE): Institute for Quality and Efficiency in Health Care; 2009 Dec 14 [updated 2010 Apr 30; cited 2010 Aug 24]. Available from: http://www.iqwig.de/blood-glucose-self-monitoring-benefit-is-not.997.en.html
Report a problem or mistake on this page
- Date modified: